The second is gastrointestinal inflammation: BPC-157s gastric origin gives it exceptional affinity for gut tissue, and the preclinical data on gut permeability, mucosal repair, and intestinal motility is the strongest body of evidence for this compound
Despite internet hype, the FDA does not approve BPC-157 for medical use and prohibits its sale for human consumption
The delayed release formula is intended to reach the lower intestines without succumbing to the harsh environment of the upper digestive system
A randomized, double-blind, placebo-controlled trial enrolled 554 adults with grass pollen allergic rhinoconjunctivitis
In addition to these, NewBioRx applies stringent QA/QC systems with lot-level testing, traceability, and documented analytical specifications, aligning with established molecular reagent quality standards and reproducibility requirements